Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Jiang, Hong ^d,e   Hampel, Harald ^b   Prvulovic, David ^b   Wallin, Anders ^c   Blennow, Kaj ^c   Li, Rena ^a   Shen, Yong ^a,d  

^a ROSKAMP INSTITUTE   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d SUN HEALTH RESEARCH INSTITUTE   (United States)

^e QINGDAO UNIVERSITY   (China)

Author keywords

ADAM 17; Alzheimer's disease; biomarker; soluble tumor necrosis factor receptor; tumor necrosis factor converting enzyme

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 80053484102     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-69     Document Type: Article

References (48)

1. The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Eikelenboom P, Veerhuis R, van Exel E, Hoozemans JJ, Rozemuller AJ, van Gool WA, Curr Alzheimer Res 2011 8 142 150 21345167
2. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. Grammas P, J Neuroinflammation 2011 8 26 10.1186/1742-2094-8-26 21439035
3. Neuroprotection by Spice-Derived Nutraceuticals: You Are What You Eat! Mol. Kannappan R, Gupta SC, Kim JH, Reuter S, Aggarwal BB, Neurobiol 2011
4. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. Marchesi VT, FASEB J 2010 25 5 13
5. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. McGeer EG, McGeer PL, J Alzheimers Dis 2011 19 355 361
6. Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease. Krause DL, Müller N, Int J Alzheimers Dis 2010 14 ii: 732806
7. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Ray B, Lahiri DK, Curr Opin Pharmacol 2009 9 434 444 10.1016/j.coph.2009.06.012 19656726
8. Distinct destructive signal pathways of neuronal death in Alzheimer's disease. Shen Y, He P, Zhong Z, McAllister C, Lindholm K, Trends Mol Med 2006 12 574 579 10.1016/j.molmed.2006.10.002 17055782 (Pubitemid 44780197)
9. Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients. Cheng X, Yang L, He P, Li R, Shen Y, J Alzheimers Dis 2010 19 621 630 20110607
10. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, Staufenbiel M, Li R, Shen Y, J Cell Biol 2007 178 829 841 10.1083/jcb.200705042 17724122 (Pubitemid 47347367)
11. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. Tobinick EL, Gross H, J Neuroinflammation 2008 5 2 10.1186/1742-2094-5-2 18184433 (Pubitemid 351149918)
12. Rationale and strategy for thalidomide as a BACE 1 inhibitor for a phase II randomized clinical trial in mild to moderate Alzheimer's disease. Sabbagh MN, Nural H, He P, Sirrel S, Belden C, Liebsack C, Li R, Shen Y, International Conference of Alzheimer's Disease (ICAD), Hawaii 2010
13. In situ localization of TNFalpha/beta, TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue. Ermert M, Pantazis C, Duncker HR, Grimminger F, Seeger W, Ermert L, Cytokine 2003 22 89 100 10.1016/S1043- 4666(03)00117-0 12849708 (Pubitemid 36808767)
14. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-a. Moss ML, Milla ME, Burkhart W, Carter HL, Chen W-J, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su J-L, Warner J, Willard D, Becherer JD, Nature 1997 385 733 736 10.1038/385733a0 9034191 (Pubitemid 27098095)
15. A metalloproteinase disintegrin that releases tumour-necrosis factor-a from cells. Black R, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP, Nature 1997 385 729 733 10.1038/385729a0 9034190 (Pubitemid 27098094)
16. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ, Korner H, Scheerens H, Hessel EM, Cyster JG, McEvoy LM, Sedgwick JD, Immunity 2001 15 533 543 10.1016/S1074-7613(01)00215-1 11672536 (Pubitemid 33016439)
17. Soluble TNF receptors are associated with A metabolism and conversion to dementia in subjects with mild cognitive impairment. Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O, Neurobiol Aging 2010 31 1877 1884 10.1016/j.neurobiolaging.2008.10.012 19070941
18. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Ewers M, Zhong Z, Bürger K, Wallin A, Blennow K, Teipel SJ, Shen Y, Hampel H, Brain 2009 131 1252 1258
19. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K, He P, McAllister C, Hampel H, Shen Y, Arch Gen Psychiatry 2007 64 718 726 10.1001/archpsyc.64.6.718 17548753 (Pubitemid 46878672)
20. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, Neurology 1984 34 939 944 6610841 (Pubitemid 14076461)
21. Clinical practice. Mild cognitive impairment. Petersen RC, N Engl J Med 2011 364 23 2227 34 10.1056/NEJMcp0910237 21651394
22. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C, Neurology 1988 39 1159 1165
23. The Composite International Diagnostic Interview. An epidemiologic Instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, Sartorius N, Towle LH, Arch Gen Psychiatry 1988 45 1069 1077 2848472 (Pubitemid 19005460)
24. Inflammation in neurodegenerative disease - a double-edged sword. Wyss-Coray T, Mucke L, Neuron 2002 35 419 432 10.1016/S0896-6273(02)00794-8 12165466 (Pubitemid 34879943)
25. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Van Eldik LJ, Thompson WL, Ralay Ranaivo H, Behanna HA, Martin Watterson D, Int Rev Neurobiol 2007 82 277 296 17678967
26. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Dembic Z, Loetscher H, Gubler U, Pan YC, Lahm HW, Gentz R, Brockhaus M, Lesslauer W, Cytokine 1990 2 231 237 10.1016/1043-4666(90)90022-L 1966549
27. Tumor necrosis factor receptor signaling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor. Tartaglia LA, Goeddel DV, J Biol Chem 1992 267 4304 4307 1311304
28. TNF-alpha gene polymorphism: clinical and biological implications. Hajeer AH, Hutchinson IV, Microsc Res Tech 2000 50 216 228 10.1002/1097-0029(20000801) 50:3<216::AID-JEMT5>3.0.CO;2-Q 10891887 (Pubitemid 30610098)
29. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. Koenigsknecht-Talboo J, Landreth GE, J Neurosci 2005 25 8240 8249 10.1523/JNEUROSCI.1808-05.2005 16148231 (Pubitemid 41292118)
30. Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. Yamamoto M, Kiyota T, Walsh SM, Liu J, Kipnis J, Ikezu T, J Immunol 2008 181 3877 3886 18768842
31. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T, Am J Pathol 2007 170 680 692 10.2353/ajpath.2007.060378 17255335 (Pubitemid 47339404)
32. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. Liao YF, Wang BJ, Cheng HT, Kuo LH, Wolfe MS, J Biol Chem 2004 279 49523 49532 10.1074/jbc.M402034200 15347683 (Pubitemid 39625840)
33. Inhibition of p75 tumor necrosis factor receptor by antisense oligonucleotides increases hypoxic injury and beta-amyloid toxicity in human neuronal cell line. Shen Y, Li R, Shiosaki K, J Biol Chem 1997 272 3550 3553 10.1074/jbc.272.6.3550 9013604 (Pubitemid 27066858)
34. An essential role for ectodomain shedding in mammalian development. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, et al. Science 1998 282 1281 1284 9812885 (Pubitemid 28524483)
35. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ, Black RA, J Biol Chem 2000 275 14608 14614 10.1074/jbc.275.19.14608 10799547 (Pubitemid 30339751)
36. Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Canault M, Leroyer AS, Peiretti F, Leseche G, Tedgui A, Bonardo B, Alessi MC, Boulanger CM, Nalbone G, Am J Pathol 2007 171 1713 1723 10.2353/ajpath.2007.070021 17872973 (Pubitemid 350158331)
37. The role of tumor necrosis factor-alpha converting enzyme in renal transplant rejection. Wang J, Li Z, Al-Lamki R, Zuo N, Bradley JR, Wang L, Am J Nephrol 2010 32 362 368 10.1159/000320467 20861614
38. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y, Nat Med 2003 9 3 4 10.1038/nm0103-3 12514700 (Pubitemid 36098241)
39. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y, Proc Natl Acad Sci USA 2004 101 3632 3637 10.1073/pnas.0205689101 14978286 (Pubitemid 38338246)
40. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA, J Biol Chem 1998 273 27765 27767 10.1074/jbc.273.43.27765 9774383 (Pubitemid 28496060)
41. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F, Proc Natl Acad Sci USA 1999 96 3922 3927 10.1073/pnas.96.7.3922 10097139 (Pubitemid 29169012)
42. Proteolytic processing and cell biological functions of the amyloid precursor protein. De Strooper B, Annaert W, J Cell Sci 2000 113 1857 1870 10806097 (Pubitemid 30386490)
43. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Blennow K, Hampel H, Weiner M, Zetterberg H, Nat Rev Neurol 2010 6 131 144 10.1038/nrneurol.2010.4 20157306
44. Effect of tumor necrosis factor-alpha converting enzyme (TACE) and metalloprotease inhibitor on amyloid precursor protein metabolism in human neurons. Blacker M, Noe MC, Carty TJ, Goodyer CG, LeBlanc AC, J Neurochem 2002 83 1349 1357 10.1046/j.1471-4159.2002.01228.x 12472889 (Pubitemid 35477474)
45. Amyloid precursor protein secretion and beta A4 amyloid generation are not mutually exclusive. Dyrks T, Monning U, Beyreuther K, Turner J, FEBS Lett 1994 349 210 214 10.1016/0014-5793(94)00671-7 8050568 (Pubitemid 24263264)
46. Amyloid precursor protein compartmentalization restricts beta-amyloid production: therapeutic targets based on BACE compartmentalization. Gandhi S, Refolo LM, Sambamurti K, J Mol Neurosci 2004 24 137 143 10.1385/JMN:24:1:137 15314262 (Pubitemid 41359179)
47. Protein kinase C activation increases release of secreted amyloid precursor protein without decreasing Abeta production in human primary neuron cultures. LeBlanc AC, Koutroumanis M, Goodyer CG, J Neurosci 1998 18 2907 2913 9526007 (Pubitemid 28163220)
48. Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. Kim ML, Zhang B, Mills IP, Milla ME, Brunden KR, Lee VM, J Neurosci 2008 28 12052 12061 10.1523/JNEUROSCI.2913-08.2008 19005070